Sabby Management, Llc - Insider Trading Tracker

Akari Therapeutics, Plc - Depositary Receipt (Common Stock)

US ˙ NasdaqCM ˙ US00972G2075

Introduction

This page provides a comprehensive analysis of the known insider trading history of Sabby Management, Llc. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

See Highest Ranking Insiders

Companies with Reported Insider Positions

The SEC filings indicate Sabby Management, Llc has reported holdings or trades in the following companies:

Security	Title	Latest Reported Holdings
US:VLCN / Volcon, Inc.	10% Owner	448,273
US:RSLS / ReShape Lifesciences Inc.	10% Owner	1,192,000
US:ROSG / Rosetta Genomics, Ltd.	10% Owner	941,693
US:CLTX / Celsus Therapeutics	10% Owner	778,030
	10% Owner	2,500,000

How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Sabby Management, Llc. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases AKTX / Akari Therapeutics, Plc - Depositary Receipt (Common Stock) - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in AKTX / Akari Therapeutics, Plc - Depositary Receipt (Common Stock). This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date	Ticker	Insider	Reported Shares	Reported Price	Adjusted Shares	Adjusted Price	Cost Basis	Days to Max
2014-04-15	CLTX	SABBY MANAGEMENT, LLC	17,100	5.0000	17,100	5.0000	85,500	64
2014-04-14	CLTX	SABBY MANAGEMENT, LLC	3,000	5.2100	3,000	5.2100	15,630
2014-04-11	CLTX	SABBY MANAGEMENT, LLC	100	5.1500	100	5.1500	515
2014-04-10	CLTX	SABBY MANAGEMENT, LLC	1,400	5.2500	1,400	5.2500	7,350
2014-04-09	CLTX	SABBY MANAGEMENT, LLC	1,075	5.5100	1,075	5.5100	5,923
2014-04-08	CLTX	SABBY MANAGEMENT, LLC	35,500	5.3600	35,500	5.3600	190,280
2014-04-07	CLTX	SABBY MANAGEMENT, LLC	16,900	5.6400	16,900	5.6400	95,316
2014-04-07	CLTX	SABBY MANAGEMENT, LLC	3,754	6.0000	3,754	6.0000	22,524
2014-04-04	CLTX	SABBY MANAGEMENT, LLC	1,000	6.0000	1,000	6.0000	6,000
2014-04-04	CLTX	SABBY MANAGEMENT, LLC	11,250	6.0800	11,250	6.0800	68,400
2014-04-02	CLTX	SABBY MANAGEMENT, LLC	2,500	6.1500	2,500	6.1500	15,375
2014-04-01	CLTX	SABBY MANAGEMENT, LLC	500	6.1800	500	6.1800	3,090
2014-04-01	CLTX	SABBY MANAGEMENT, LLC	7,375	6.0800	7,375	6.0800	44,840
2014-04-01	CLTX	SABBY MANAGEMENT, LLC	7,496	6.1200	7,496	6.1200	45,876
2014-03-31	CLTX	SABBY MANAGEMENT, LLC	7,936	6.3500	7,936	6.3500	50,394
2014-03-27	CLTX	SABBY MANAGEMENT, LLC	1,700	6.6100	1,700	6.6100	11,237
2014-03-26	CLTX	SABBY MANAGEMENT, LLC	900	6.8600	900	6.8600	6,174
2014-03-26	CLTX	SABBY MANAGEMENT, LLC	13,300	6.6500	13,300	6.6500	88,445
2014-03-25	CLTX	SABBY MANAGEMENT, LLC	303	6.9000	303	6.9000	2,091
2014-03-24	CLTX	SABBY MANAGEMENT, LLC	2,400	6.7100	2,400	6.7100	16,104
2014-03-21	CLTX	SABBY MANAGEMENT, LLC	4,900	6.8300	4,900	6.8300	33,467
2014-03-20	CLTX	SABBY MANAGEMENT, LLC	3,800	6.9000	3,800	6.9000	26,220
2014-03-17	CLTX	SABBY MANAGEMENT, LLC	2,400	6.6500	2,400	6.6500	15,960

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

AKTX / Akari Therapeutics, Plc - Depositary Receipt (Common Stock) Insider Trades

Insider Sales AKTX / Akari Therapeutics, Plc - Depositary Receipt (Common Stock) - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in AKTX / Akari Therapeutics, Plc - Depositary Receipt (Common Stock). A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date	Ticker	Insider	Reported Shares	Reported Price	Adjusted Shares	Adjusted Price	Cost Basis	Days to Min	Price at Min	Max Loss Avoided ($)	Max Loss Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

Insider Purchases EMPD / Empery Digital Inc. - Short Term Profit Analysis

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date	Ticker	Insider	Reported Shares	Reported Price	Adjusted Shares	Adjusted Price	Cost Basis	Days to Max	Price at Max	Max Profit ($)	Max Return (%)
2024-08-30	VLCN	SABBY MANAGEMENT, LLC	10,000	1.4156	1,250	11.3248	14,156	321	21.6100	12,856	90.82
2024-08-29	VLCN	SABBY MANAGEMENT, LLC	3,064	1.4500	383	11.6000	4,443
2024-08-28	VLCN	SABBY MANAGEMENT, LLC	21,998	1.4959	2,750	11.9672	32,907
2024-08-26	VLCN	SABBY MANAGEMENT, LLC	3,194	1.5454	399	12.3632	4,936
2024-08-23	VLCN	SABBY MANAGEMENT, LLC	3,500	1.5484	438	12.3872	5,419
2024-08-22	VLCN	SABBY MANAGEMENT, LLC	3,598	1.4872	450	11.8976	5,351
2024-08-21	VLCN	SABBY MANAGEMENT, LLC	17,757	1.5023	2,220	12.0184	26,676
2024-08-20	VLCN	SABBY MANAGEMENT, LLC	10,953	1.5670	1,369	12.5360	17,163
2024-08-19	VLCN	SABBY MANAGEMENT, LLC	5,065	1.5946	633	12.7568	8,077
2024-08-16	VLCN	SABBY MANAGEMENT, LLC	16,974	1.4344	2,122	11.4752	24,348
2024-08-15	VLCN	SABBY MANAGEMENT, LLC	27,514	1.5094	3,439	12.0752	41,530
2024-08-14	VLCN	SABBY MANAGEMENT, LLC	20,158	1.6193	2,520	12.9544	32,642
2024-08-13	VLCN	SABBY MANAGEMENT, LLC	3,372	1.6795	422	13.4360	5,663
2024-08-12	VLCN	SABBY MANAGEMENT, LLC	6,087	1.6421	761	13.1368	9,995
2024-08-09	VLCN	SABBY MANAGEMENT, LLC	7,116	1.6445	890	13.1560	11,702
2024-08-08	VLCN	SABBY MANAGEMENT, LLC	8,019	1.6494	1,002	13.1952	13,227
2024-08-07	VLCN	SABBY MANAGEMENT, LLC	43,756	1.7558	5,470	14.0464	76,827
2024-08-06	VLCN	SABBY MANAGEMENT, LLC	3,284	1.8206	410	14.5648	5,979
2024-08-05	VLCN	SABBY MANAGEMENT, LLC	74,574	1.8097	9,322	14.4776	134,957
2024-08-02	VLCN	SABBY MANAGEMENT, LLC	40,349	1.9443	5,044	15.5544	78,451

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

EMPD / Empery Digital Inc. Insider Trades

Insider Sales EMPD / Empery Digital Inc. - Short Term Loss Analysis

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date	Ticker	Insider	Reported Shares	Reported Price	Adjusted Shares	Adjusted Price	Cost Basis	Days to Min	Price at Min	Max Loss Avoided ($)	Max Loss Avoided (%)
2024-08-22	VLCN	SABBY MANAGEMENT, LLC	32,794	2.0500	4,099	16.4000	67,228	281	0.5672	-64,902	-96.54
2024-08-06	VLCN	SABBY MANAGEMENT, LLC	512	2.0507	64	16.4056	1,050

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

Insider Trading History

This table shows the complete list of insider trades made by Sabby Management, Llc as disclosed to the Securities Exchange Commission (SEC).

File Date	Tran Date	Form	Ticker	Security	Code	Shares	Remaining Shares	Percent Change	Share Price	Tran Value	Remaining Value
2024-10-17	2024-10-15	4	VLCN	Volcon, Inc. Common Stock	J - Other	-774,569	448,273	-63.34
2024-09-03	2024-08-30	4	VLCN	Volcon, Inc. Common Stock	P - Purchase	10,000	774,569	1.31	1.42	14,156	1,096,480
2024-08-30	2024-08-29	4	VLCN	Volcon, Inc. Common Stock	P - Purchase	3,064	764,569	0.40	1.45	4,443	1,108,625
2024-08-30	2024-08-28	4	VLCN	Volcon, Inc. Common Stock	P - Purchase	21,998	761,505	2.97	1.50	32,907	1,139,135
2024-08-28	2024-08-26	4	VLCN	Volcon, Inc. Common Stock	P - Purchase	3,194	739,507	0.43	1.55	4,936	1,142,834
2024-08-26	2024-08-23	4	VLCN	Volcon, Inc. Common Stock	P - Purchase	3,500	736,313	0.48	1.55	5,419	1,140,107
2024-08-26	2024-08-22	4	VLCN	Volcon, Inc. Common Stock	S - Sale	-32,794	732,813	-4.28	2.05	-67,228	1,502,267
2024-08-26	2024-08-22	4	VLCN	Volcon, Inc. Common Stock	P - Purchase	3,598	765,607	0.47	1.49	5,351	1,138,611
2024-08-22	2024-08-21	4	VLCN	Volcon, Inc. Common Stock	P - Purchase	17,757	762,009	2.39	1.50	26,676	1,144,766
2024-08-22	2024-08-20	4	VLCN	Volcon, Inc. Common Stock	P - Purchase	10,953	744,252	1.49	1.57	17,163	1,166,243
2024-08-20	2024-08-19	4	VLCN	Volcon, Inc. Common Stock	P - Purchase	5,065	733,299	0.70	1.59	8,077	1,169,319
2024-08-20	2024-08-16	4	VLCN	Volcon, Inc. Common Stock	P - Purchase	16,974	728,234	2.39	1.43	24,348	1,044,579
2024-08-16	2024-08-15	4	VLCN	Volcon, Inc. Common Stock	P - Purchase	27,514	711,260	4.02	1.51	41,530	1,073,576
2024-08-16	2024-08-14	4	VLCN	Volcon, Inc. Common Stock	P - Purchase	20,158	683,746	3.04	1.62	32,642	1,107,190
2024-08-14	2024-08-13	4	VLCN	Volcon, Inc. Common Stock	P - Purchase	3,372	663,588	0.51	1.68	5,663	1,114,496
2024-08-14	2024-08-12	4	VLCN	Volcon, Inc. Common Stock	P - Purchase	6,087	660,216	0.93	1.64	9,995	1,084,141
2024-08-12	2024-08-09	4	VLCN	Volcon, Inc. Common Stock	P - Purchase	7,116	654,129	1.10	1.64	11,702	1,075,715
2024-08-12	2024-08-08	4	VLCN	Volcon, Inc. Common Stock	P - Purchase	8,019	647,013	1.25	1.65	13,227	1,067,183
2024-08-08	2024-08-07	4	VLCN	Volcon, Inc. Common Stock	P - Purchase	43,756	638,994	7.35	1.76	76,827	1,121,946
2024-08-08	2024-08-06	4	VLCN	Volcon, Inc. Common Stock	S - Sale	-512	595,238	-0.09	2.05	-1,050	1,220,655
2024-08-08	2024-08-06	4	VLCN	Volcon, Inc. Common Stock	P - Purchase	3,284	595,750	0.55	1.82	5,979	1,084,622
2024-08-06		3	VLCN	Volcon, Inc. Common Stock			477,543
2024-08-06	2024-08-05	4	VLCN	Volcon, Inc. Common Stock	P - Purchase	74,574	592,466	14.40	1.81	134,957	1,072,186
2024-08-06	2024-08-02	4	VLCN	Volcon, Inc. Common Stock	P - Purchase	40,349	517,892	8.45	1.94	78,451	1,006,937
2019-02-04	2019-02-01	4	RSLS	ReShape Lifesciences Inc. Series E Convertible Preferred Stock	J - Other	1,192,000	1,192,000
2019-02-04	2019-02-01	4	RSLS	ReShape Lifesciences Inc. Common Stock	P - Purchase	-1,192,000	507	-99.96
2019-02-04	2019-01-31	4	RSLS	ReShape Lifesciences Inc. Common Stock	P - Purchase	10,301	1,192,507	0.87	0.27	2,815	325,912
2019-01-31	2019-01-30	4	RSLS	ReShape Lifesciences Inc. Common Stock	P - Purchase	48,000	1,182,206	4.23	0.28	13,440	331,018
2019-01-31	2019-01-29	4	RSLS	ReShape Lifesciences Inc. Common Stock	P - Purchase	12,200	1,134,206	1.09	0.28	3,390	315,196
2019-01-28	2019-01-25	4	RSLS	ReShape Lifesciences Inc. Common Stock	P - Purchase	15,595	1,122,006	1.41	0.27	4,237	304,849
2019-01-28	2019-01-24	4	RSLS	ReShape Lifesciences Inc. Common Stock	P - Purchase	6,190	1,106,411	0.56	0.26	1,578	282,135
2019-01-24	2019-01-22	4	RSLS	ReShape Lifesciences Inc. Common Stock	P - Purchase	5,766	1,100,221	0.53	0.28	1,609	307,072
2019-01-22	2019-01-18	4	RSLS	ReShape Lifesciences Inc. Common Stock	P - Purchase	24,334	1,094,455	2.27	0.28	6,787	305,243
2019-01-22	2019-01-17	4	RSLS	ReShape Lifesciences Inc. Common Stock	P - Purchase	52	1,070,121	0.00	0.28	15	299,634
2019-01-17	2019-01-16	4	RSLS	ReShape Lifesciences Inc. Common Stock	P - Purchase	4,700	1,070,069	0.44	0.26	1,236	281,428
2019-01-17	2019-01-16	4	RSLS	ReShape Lifesciences Inc. Common Stock	P - Purchase	21,961	1,065,369	2.10	0.27	5,936	287,969
2019-01-17	2019-01-15	4	RSLS	ReShape Lifesciences Inc. Common Stock	P - Purchase	167,760	1,043,408	19.16	0.24	39,440	245,305
2019-01-17		3	RSLS	ReShape Lifesciences Inc. Common Stock			2,086,816
2019-01-17		3	RSLS	ReShape Lifesciences Inc. Common Stock			2,086,816
2019-01-17		3	RSLS	ReShape Lifesciences Inc. Common Stock			2,086,816
2018-04-27	2018-04-26	4	ROSG	Rosetta Genomics Ltd. ADR Shares (each one equal to 2 ordinary shares)	P - Purchase	7,085	941,693	0.76	0.35	2,480	329,593
2018-03-19	2018-03-16	4	ROSG	Rosetta Genomics Ltd. ADR Shares (each one equal to 2 ordinary shares)	P - Purchase	9	934,608	0.00	0.42	4	392,629
2018-03-19	2018-03-16	4	ROSG	Rosetta Genomics Ltd. ADR Shares (each one equal to 2 ordinary shares)	P - Purchase	33,413	934,599	3.71	0.44	14,545	406,831
2018-03-19	2018-03-16	4	ROSG	Rosetta Genomics Ltd. ADR Shares (each one equal to 2 ordinary shares)	P - Purchase	9,247	901,186	1.04	0.43	3,971	386,969
2018-03-19	2018-03-16	4	ROSG	Rosetta Genomics Ltd. ADR Shares (each one equal to 2 ordinary shares)	P - Purchase	20,229	891,939	2.32	0.43	8,620	380,055
2018-03-19	2018-03-16	4	ROSG	Rosetta Genomics Ltd. ADR Shares (each one equal to 2 ordinary shares)	P - Purchase	1,400	871,710	0.16	0.42	590	367,077
2018-03-16	2018-03-15	4	ROSG	Rosetta Genomics Ltd. ADR Shares (each one equal to 2 ordinary shares)	P - Purchase	14,400	870,310	1.68	0.42	6,055	365,965
2018-03-16	2018-03-15	4	ROSG	Rosetta Genomics Ltd. ADR Shares (each one equal to 2 ordinary shares)	P - Purchase	13,545	855,910	1.61	0.42	5,689	359,482
2018-03-16	2018-03-15	4	ROSG	Rosetta Genomics Ltd. ADR Shares (each one equal to 2 ordinary shares)	P - Purchase	3,566	842,365	0.43	0.42	1,498	353,793
2018-03-16	2018-03-15	4	ROSG	Rosetta Genomics Ltd. ADR Shares (each one equal to 2 ordinary shares)	P - Purchase	34	838,799	0.00	0.42	14	352,296
2018-03-16	2018-03-15	4	ROSG	Rosetta Genomics Ltd. ADR Shares (each one equal to 2 ordinary shares)	P - Purchase	15,025	838,765	1.82	0.42	6,318	352,701
2018-03-16	2018-03-14	4	ROSG	Rosetta Genomics Ltd. ADR Shares (each one equal to 2 ordinary shares)	P - Purchase	50,020	823,740	6.46	0.42	21,013	346,053
2018-03-16	2018-03-14	4	ROSG	Rosetta Genomics Ltd. ADR Shares (each one equal to 2 ordinary shares)	P - Purchase	17,900	773,720	2.37	0.42	7,590	328,057
2018-03-16	2018-03-14	4	ROSG	Rosetta Genomics Ltd. ADR Shares (each one equal to 2 ordinary shares)	P - Purchase	200	755,820	0.03	0.42	84	317,444
2018-03-16	2018-03-14	4	ROSG	Rosetta Genomics Ltd. ADR Shares (each one equal to 2 ordinary shares)	P - Purchase	4,271	755,620	0.57	0.42	1,794	317,360
2018-03-16	2018-03-14	4	ROSG	Rosetta Genomics Ltd. ADR Shares (each one equal to 2 ordinary shares)	P - Purchase	800	751,349	0.11	0.42	336	315,491
2018-03-14	2018-03-13	4	ROSG	Rosetta Genomics Ltd. ADR Shares (each one equal to 2 ordinary shares)	P - Purchase	6,329	750,549	0.85	0.42	2,658	315,231
2018-03-14	2018-03-13	4	ROSG	Rosetta Genomics Ltd. ADR Shares (each one equal to 2 ordinary shares)	P - Purchase	30,990	744,220	4.35	0.42	13,025	312,796
2018-03-14	2018-03-12	4	ROSG	Rosetta Genomics Ltd. ADR Shares (each one equal to 2 ordinary shares)	P - Purchase	10,000	713,230	1.42	0.42	4,200	299,557
2018-03-14	2018-03-12	4	ROSG	Rosetta Genomics Ltd. ADR Shares (each one equal to 2 ordinary shares)	P - Purchase	12,390	703,230	1.79	0.41	5,081	288,395
2018-03-14	2018-03-12	4	ROSG	Rosetta Genomics Ltd. ADR Shares (each one equal to 2 ordinary shares)	P - Purchase	10,605	690,840	1.56	0.42	4,442	289,393
2018-03-14	2018-03-12	4	ROSG	Rosetta Genomics Ltd. ADR Shares (each one equal to 2 ordinary shares)	P - Purchase	24,162	680,235	3.68	0.42	10,114	284,746
2018-03-14	2018-03-12	4	ROSG	Rosetta Genomics Ltd. ADR Shares (each one equal to 2 ordinary shares)	P - Purchase	24,600	656,073	3.90	0.42	10,295	274,567
2018-03-14	2018-03-12	4	ROSG	Rosetta Genomics Ltd. ADR Shares (each one equal to 2 ordinary shares)	P - Purchase	21,800	631,473	3.58	0.41	8,975	259,977
2018-03-14	2018-03-12	4	ROSG	Rosetta Genomics Ltd. ADR Shares (each one equal to 2 ordinary shares)	P - Purchase	11,521	609,673	1.93	0.41	4,724	249,966
2018-03-14	2018-03-12	4	ROSG	Rosetta Genomics Ltd. ADR Shares (each one equal to 2 ordinary shares)	P - Purchase	2,604	598,152	0.44	0.42	1,093	251,164
2018-03-14	2018-03-12	4	ROSG	Rosetta Genomics Ltd. ADR Shares (each one equal to 2 ordinary shares)	P - Purchase	454	595,548	0.08	0.40	182	238,815
2018-03-14	2018-03-12	4	ROSG	Rosetta Genomics Ltd. ADR Shares (each one equal to 2 ordinary shares)	P - Purchase	20,373	595,094	3.54	0.42	8,555	249,880
2018-03-14		3	ROSG	Rosetta Genomics Ltd. ADR Shares (each one equal to 2 ordinary shares)			1,426,460
2018-03-14		3	ROSG	Rosetta Genomics Ltd. ADR Shares (each one equal to 2 ordinary shares)			1,426,460
2018-03-14		3	ROSG	Rosetta Genomics Ltd. ADR Shares (each one equal to 2 ordinary shares)			1,426,460
2014-04-17	2014-04-15	4	CLTX	Celsus Therapeutics Plc. Common Stock	P - Purchase	17,100	778,030	2.25	5.00	85,500	3,890,150
2014-04-17	2014-04-14	4	CLTX	Celsus Therapeutics Plc. Common Stock	P - Purchase	3,000	760,930	0.40	5.21	15,630	3,964,445
2014-04-11	2014-04-11	4	CLTX	Celsus Therapeutics Plc. Common Stock	P - Purchase	100	757,930	0.01	5.15	515	3,903,340
2014-04-11	2014-04-10	4	CLTX	Celsus Therapeutics Plc. Common Stock	P - Purchase	1,400	757,830	0.19	5.25	7,350	3,978,608
2014-04-11	2014-04-09	4	CLTX	Celsus Therapeutics Plc. Common Stock	P - Purchase	1,075	756,430	0.14	5.51	5,923	4,167,929
2014-04-08	2014-04-08	4	CLTX	Celsus Therapeutics Plc. Common Stock	P - Purchase	35,500	755,355	4.93	5.36	190,280	4,048,703
2014-04-08	2014-04-07	4	CLTX	Celsus Therapeutics Plc. Common Stock	P - Purchase	3,754	719,855	0.52	6.00	22,524	4,319,130
2014-04-08	2014-04-07	4	CLTX	Celsus Therapeutics Plc. Common Stock	P - Purchase	16,900	716,101	2.42	5.64	95,316	4,038,810
2014-04-08	2014-04-04	4	CLTX	Celsus Therapeutics Plc. Common Stock	P - Purchase	11,250	699,201	1.64	6.08	68,400	4,251,142
2014-04-08	2014-04-04	4	CLTX	Celsus Therapeutics Plc. Common Stock	P - Purchase	1,000	687,951	0.15	6.00	6,000	4,127,706
2014-04-02	2014-04-02	4	CLTX	Celsus Therapeutics Plc. Common stock	P - Purchase	2,500	686,951	0.37	6.15	15,375	4,224,749
2014-04-02	2014-04-01	4	CLTX	Celsus Therapeutics Plc. Common stock	P - Purchase	7,496	684,451	1.11	6.12	45,876	4,188,840
2014-04-02	2014-04-01	4	CLTX	Celsus Therapeutics Plc. Common Stock	P - Purchase	7,375	676,955	1.10	6.08	44,840	4,115,886
2014-04-02	2014-04-01	4	CLTX	Celsus Therapeutics Plc. Common Stock	P - Purchase	500	669,580	0.07	6.18	3,090	4,138,004
2014-04-02	2014-03-31	4	CLTX	Celsus Therapeutics Plc. Common Shares	P - Purchase	7,936	669,080	1.20	6.35	50,394	4,248,658
2014-04-02	2014-03-17	4	CLTX	Celsus Therapeutics Plc. Common Shares	P - Purchase	2,400	661,144	0.36	6.65	15,960	4,396,608
2014-03-27	2014-03-27	4	CLTX	Celsus Therapeutics Plc. Common Stock	P - Purchase	1,700	658,744	0.26	6.61	11,237	4,354,298
2014-03-27	2014-03-26	4	CLTX	Celsus Therapeutics Plc. Common Stock	P - Purchase	13,300	657,044	2.07	6.65	88,445	4,369,343
2014-03-27	2014-03-26	4	CLTX	Celsus Therapeutics Plc. Common Stock	P - Purchase	900	643,744	0.14	6.86	6,174	4,416,084
2014-03-27	2014-03-25	4	CLTX	Celsus Therapeutics Plc. Common Stock	P - Purchase	303	642,844	0.05	6.90	2,091	4,435,624
2014-03-24	2014-03-24	4	CLTX	Celsus Therapeutics Plc. Common Stock	P - Purchase	2,400	642,541	0.37	6.71	16,104	4,311,450
2014-03-24	2014-03-21	4	CLTX	Celsus Therapeutics Plc. Common Stock	P - Purchase	4,900	640,141	0.77	6.83	33,467	4,372,163
2014-03-24	2014-03-20	4	CLTX	Celsus Therapeutics Plc. Common Stock	P - Purchase	3,800	635,241	0.60	6.90	26,220	4,383,163
2014-03-14		3	CLTX	Celsus Therapeutics Plc. Common Stock			1,262,882
2014-03-14		3	CLTX	Celsus Therapeutics Plc. Common Stock			1,262,882
2014-03-14		3	CLTX	Celsus Therapeutics Plc. Common Stock			1,262,882
2014-03-14		3	CLTX	Celsus Therapeutics Plc. Common Stock			1,262,882
2012-11-09	2012-11-08	4	path	NUPATHE INC. Series A Preferred Stock	J - Other	0	2,500,000	0.00
2012-11-09	2012-10-23	4	path	NUPATHE INC. Warrant	J - Other	0	2,500,000	0.00

Open market or private purchase of non-derivative or derivative security

Open market or private sale of non-derivative or derivative security

Grant, award, or other acquisition of securities from the company (such as an option)

Conversion of derivative

Sale or transfer of securities back to the company

Payment of exercise price or tax liability using portion of securities received from the company

Gift of securities by or to the insider

Equity swaps and similar hedging transactions

Exercise or conversion of derivative security received from the company (such as an option)

A transaction voluntarily reported on Form 4

Other (accompanied by a footnote describing the transaction)